"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA APPROVES ATEZOLIZUMAB (TECENTRIQ) FOR THE TREATMENT OF PATIENT WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

FDA APPROVES ATEZOLIZUMAB (TECENTRIQ) FOR THE TREATMENT OF PATIENT WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

25 Apr 2017 1:36 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved atezolizumab (Tecentriq) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software